Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
48-week extension study of bimekizumab in moderate to severe chronic plaque psoriasis
2016-001892-57Phase 2Completed
- Sponsor
- UCB
- Start
- Sep 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in psoriasis and plaque psoriasis comparing Bimekizumab Q4W with Placebo (2 arms). Primary endpoint: Incidence of Treatment Emergent Adverse Events (TEAEs) adjusted by duration of subject exposure to treatment. Started Sep 2016; status: completed.
02
Drugs
bimekizumab
03
Conditions
psoriasisplaque psoriasis
Beyond the preview
Go deeper on 2016-001892-57.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001892-57.